Scarica l'app Stockscreener
20.27
0.37%
-0.075
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CSTL Giù?
Forum
Previsione
Precedente Chiudi:
$20.34
Aprire:
$20.21
Volume 24 ore:
171.35K
Relative Volume:
0.40
Capitalizzazione di mercato:
$520.86M
Reddito:
$219.79M
Utile/perdita netta:
$-57.47M
Rapporto P/E:
-9.4256
EPS:
-2.15
Flusso di cassa netto:
$-19.25M
1 W Prestazione:
+4.08%
1M Prestazione:
+24.55%
6M Prestazione:
-27.73%
1 anno Prestazione:
-4.68%
Intervallo 1D:
$20.00
$20.57
Intervallo di 1 settimana:
$19.35
$20.63
Portata 52W:
$15.45
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
Nome
Castle Biosciences Inc
Settore
Industria
Telefono
866-788-9007
Indirizzo
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Confronta CSTL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
20.26 | 520.86M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
428.25 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
203.39 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
544.52 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
121.26 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
164.65 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2021-04-30 | Iniziato | Lake Street | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | Reiterato | Canaccord Genuity | Buy |
| 2019-08-19 | Iniziato | BTIG Research | Buy |
| 2019-08-19 | Iniziato | Canaccord Genuity | Buy |
| 2019-08-19 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-19 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Castle Biosciences Inc Borsa (CSTL) Ultime notizie
Castle Biosciences partners with SciBase for diagnostic tests - MSN
Castle Biosciences Inc (CSTL) Stock Price Down 4.54% on Jun 17 - GuruFocus
Castle Biosciences, SciBase Partner to Develop Predictive Tests for Skin Conditions - marketscreener.com
Castle Biosciences partners with SciBase for diagnostic tests (CSTL) - Seeking Alpha
Castle Biosciences enters collaboration, license agreement with Scibase to develop diagnostic tests for dermatologic diseases - MarketScreener
SciBase resolves on a directed share issue of SEK 19 million and announces its intention to carry out an additional directed share issue of approximately SEK 11 million - Yahoo Finance
Castle Biosciences Enters Collaboration and License Agreement wi - GuruFocus
Castle Biosciences (CSTL) Partners with SciBase for Dermatology Advancements | CSTL Stock News - GuruFocus
Castle Biosciences partners with SciBase to develop atopic dermatitis test - Investing.com
SciBase signs license agreement with Castle Biosciences to develop dermatology diagnostic tests - marketscreener.com
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases - The Manila Times
Castle Biosciences Enters Collaboration and License - GlobeNewswire
New Diagnostic Test Could Predict Atopic Dermatitis Flares Before Symptoms Appear - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Harbor Capital Advisors Inc. - Defense World
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards® - Barchart.com
Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention | CSTL Stock News - GuruFocus
Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention - The Manila Times
Castle Biosciences’ Chief Executive Officer Derek Maetzold - GlobeNewswire
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion ... - Bluefield Daily Telegraph
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention - Barchart.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Two Sigma Advisers LP Acquires New Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Squarepoint Ops LLC Lowers Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards® - The Manila Times
Castle Biosciences’ Founder, President and CEO Derek - GlobeNewswire
ProShare Advisors LLC Makes New $230,000 Investment in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences, Inc. (CSTL) Unveils Largest Real-World Melanoma Risk Study at ASCO 2025 - Insider Monkey
Castle Biosciences Presents Innovative Research on Melanoma Risk Stratification at ASCO 2025 - Nasdaq
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's - GlobeNewswire
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Rating of “Buy” by Brokerages - Defense World
Man Group plc Buys Shares of 13,302 Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Nuveen Asset Management LLC Has $12.41 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Deutsche Bank AG Buys 7,495 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Bank of America Corp DE Raises Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences amends charter, stockholders vote By Investing.com - Investing.com India
Castle Biosciences Holds Annual Stockholders Meeting - TipRanks
Castle Biosciences amends charter, stockholders vote - Investing.com
Some Confidence Is Lacking In Castle Biosciences, Inc. (NASDAQ:CSTL) As Shares Slide 28% - simplywall.st
Castle Biosciences stock hits 52-week low at $15.66 By Investing.com - Investing.com Australia
Scotiabank Issues Pessimistic Forecast for Castle Biosciences (NASDAQ:CSTL) Stock Price - Defense World
Castle Biosciences (CSTL) Target Price Updated by Scotiabank | C - GuruFocus
Castle Biosciences (CSTL) Target Price Updated by Scotiabank | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Price Target Revised by Scotiabank | C - GuruFocus
Castle Biosciences to Present at the 2025 Jefferies Global Healt - GuruFocus
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference | CSTL Stock News - GuruFocus
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Castle Biosciences Executive Team Reveals Strategic Updates at Jefferies Healthcare Conference - Stock Titan
90,563 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Purchased by D. E. Shaw & Co. Inc. - Defense World
Ameriprise Financial Inc. Has $8.42 Million Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Northern Trust Corp Boosts Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Jane Street Group LLC Reduces Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences Inc Azioni (CSTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Castle Biosciences Inc Azioni (CSTL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Apr 21 '25 |
Sale |
21.52 |
4,408 |
94,851 |
4,275 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Apr 21 '25 |
Sale |
21.52 |
1,236 |
26,596 |
74,627 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Apr 09 '25 |
Sale |
20.22 |
3,647 |
73,739 |
4,440 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Apr 09 '25 |
Sale |
20.22 |
1,023 |
20,684 |
75,863 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Apr 08 '25 |
Sale |
20.03 |
761 |
15,243 |
4,577 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Apr 08 '25 |
Sale |
20.03 |
213 |
4,266 |
76,886 |
1.29%
0.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):